Merck & Co., Inc. $MRK Position Boosted by Arete Wealth Advisors LLC

Key Points

• Arete Wealth Advisors increased its Merck position by 30.8% in the first quarter to 51,371 shares valued at $6.18 million. Institutional investors collectively own 76.07% of MRK.
• Analysts maintain a generally positive outlook, with a consensus rating of “Moderate Buy” and a $134.50 price target. Recent targets range from $120 to $142.
• Merck reported quarterly revenue of $16.29 billion, exceeding estimates, and declared a $0.85-per-share quarterly dividend, equal to a 2.6% annualized yield. Investors are also monitoring upcoming earnings, Keytruda’s growth prospects and weakness in Gardasil sales.

Arete Wealth Advisors LLC raised its position in shares of Merck & Co., Inc. (NYSE:MRK - Free Report) by 30.8% during the 1st quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 51,371 shares of the company's stock after buying an additional 12,096 shares during the quarter. Arete Wealth Advisors LLC's holdings in Merck & Co., Inc. were worth $6,179,000 at the end of the most recent quarter.

A number of other large investors also recently bought and sold shares of the company. Vanguard Group Inc. raised its position in shares of Merck & Co., Inc. by 0.9% during the 4th quarter. Vanguard Group Inc. now owns 254,322,763 shares of the company's stock worth $26,770,014,000 after purchasing an additional 2,185,853 shares during the period. State Street Corp lifted its stake in Merck & Co., Inc. by 1.6% in the fourth quarter. State Street Corp now owns 120,040,168 shares of the company's stock valued at $12,737,504,000 after buying an additional 1,859,990 shares during the last quarter. Wellington Management Group LLP lifted its position in Merck & Co., Inc. by 14.8% in the 4th quarter. Wellington Management Group LLP now owns 86,435,458 shares of the company's stock valued at $9,098,196,000 after purchasing an additional 11,156,354 shares during the last quarter. Geode Capital Management LLC boosted its stake in Merck & Co., Inc. by 0.4% during the 4th quarter. Geode Capital Management LLC now owns 60,047,984 shares of the company's stock valued at $6,307,572,000 after purchasing an additional 249,110 shares during the period. Finally, Morgan Stanley grew its holdings in Merck & Co., Inc. by 0.8% in the 4th quarter. Morgan Stanley now owns 44,946,021 shares of the company's stock worth $4,731,018,000 after buying an additional 359,486 shares in the last quarter. Institutional investors own 76.07% of the company's stock.

Analysts Set New Price Targets

Several brokerages have weighed in on MRK. Wall Street Zen downgraded Merck & Co., Inc. from a "buy" rating to a "hold" rating in a research note on Monday, July 20th. CICC Research initiated coverage on Merck & Co., Inc. in a research note on Wednesday, June 24th. They issued an "outperform" rating and a $138.00 price target for the company. Cantor Fitzgerald reaffirmed a "neutral" rating and issued a $120.00 price objective on shares of Merck & Co., Inc. in a report on Monday, July 6th. Royal Bank Of Canada reissued an "outperform" rating and set a $142.00 target price on shares of Merck & Co., Inc. in a report on Wednesday, July 8th. Finally, BMO Capital Markets upped their target price on Merck & Co., Inc. from $135.00 to $142.00 and gave the stock an "outperform" rating in a research report on Monday, July 13th. Thirteen investment analysts have rated the stock with a Buy rating and seven have issued a Hold rating to the stock. According to MarketBeat, the company presently has a consensus rating of "Moderate Buy" and a consensus target price of $134.50.

Merck & Co., Inc. Stock Up 0.5%

Shares of NYSE:MRK opened at $130.49 on Friday. The firm has a 50 day simple moving average of $123.17 and a 200 day simple moving average of $118.46. Merck & Co., Inc. has a 52 week low of $77.53 and a 52 week high of $135.05. The company has a debt-to-equity ratio of 1.02, a quick ratio of 1.06 and a current ratio of 1.30. The company has a market cap of $322.28 billion, a PE ratio of 36.76, a price-to-earnings-growth ratio of 5.15 and a beta of 0.19.

Merck & Co., Inc. (NYSE:MRK - Get Free Report) last posted its quarterly earnings results on Thursday, April 30th. The company reported ($1.28) earnings per share for the quarter, beating the consensus estimate of ($1.47) by $0.19. The firm had revenue of $16.29 billion for the quarter, compared to analyst estimates of $15.85 billion. Merck & Co., Inc. had a return on equity of 27.55% and a net margin of 13.59%.Merck & Co., Inc.'s quarterly revenue was up 4.9% on a year-over-year basis. During the same period in the previous year, the firm earned $2.22 earnings per share. As a group, research analysts expect that Merck & Co., Inc. will post 2.74 earnings per share for the current year.

Merck & Co., Inc. Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Wednesday, October 7th. Investors of record on Tuesday, September 15th will be given a dividend of $0.85 per share. The ex-dividend date of this dividend is Tuesday, September 15th. This represents a $3.40 dividend on an annualized basis and a yield of 2.6%. Merck & Co., Inc.'s dividend payout ratio (DPR) is presently 95.77%.

Key Headlines Impacting Merck & Co., Inc.

Here are the key news stories impacting Merck & Co., Inc. this week:

• Positive Sentiment: Merck’s launch of subcutaneous Keytruda, known as Qlex, and other lifecycle extensions could preserve the drug’s commercial momentum and support exclusivity through 2039. Recent regulatory approvals, pipeline progress and the acquisitions of Terns and Cidara also broaden the company’s oncology and virology prospects. Merck: Heading Into Q2 Earnings, The Keytruda Cliff Looks Increasingly Less Steep
• Positive Sentiment: Analyst estimates have improved, including Erste Group’s modest increase in its FY2027 EPS forecast to $9.54 from $9.52. Barclays has also forecast strong potential appreciation for MRK, reinforcing the constructive sentiment around the shares. Barclays Forecasts Strong Price Appreciation for Merck & Co., Inc. Stock
• Positive Sentiment: Merck declared a quarterly dividend of $0.85 per share, payable October 7 to shareholders of record September 15. The dividend provides ongoing income support, with a reported annualized yield of about 2.6%.
• Neutral Sentiment: MRK is scheduled to release second-quarter 2026 results before the market opens on August 4. Consensus calls for approximately $16.33 billion in sales and a loss of $0.26 per share, with acquisition costs likely affecting reported earnings. Investors will watch Keytruda demand, Gardasil performance and management’s outlook. Should You Buy, Sell or Hold Merck Stock Ahead of Q2 Earnings?
• Neutral Sentiment: Merck and Wellcome’s Hilleman Laboratories are preparing an experimental Ebola vaccine for clinical trials. The initiative supports Merck’s public-health profile but is unlikely to materially affect near-term financial results. Merck, Wellcome Partner With Global Health Group to Make Ebola Vaccine for Clinical Trials
• Negative Sentiment: After a roughly 17% rally since its latest quarterly results, MRK may already reflect much of the favorable Keytruda and pipeline news. Analysts characterize its longer-term valuation as justified rather than clearly inexpensive, while Gardasil weakness and the approaching earnings event remain risks. Merck Stock Looks Cheap on Cash Flow but Fair on Earnings

Merck & Co., Inc. Company Profile

Merck & Co, Inc is a global biopharmaceutical company engaged in the discovery, development, manufacture and marketing of prescription medicines, vaccines, biologic therapies and animal health products. Its portfolio spans multiple therapeutic areas with a particular emphasis on oncology, vaccines and infectious disease, as well as therapies for metabolic and chronic conditions. Among its well-known products are the cancer immunotherapy Keytruda (pembrolizumab) and the human papillomavirus vaccine Gardasil; the company also markets a range of medicines and vaccines for veterinary use through Merck Animal Health.

Founded in the late 19th century as the U.S.

Want to see what other hedge funds are holding MRK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Merck & Co., Inc. (NYSE:MRK - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.